Benzinga · Aug 17, 2026
Canaccord Genuity Maintains Buy on Cardiol Therapeutics, Raises Price Target to $10
Canaccord Genuity analyst Edward Nash maintains Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and raises the price target from $8 to $10.
CR
NASDAQ · CRDL
Cardiol Therapeutics Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$1.86
Down-$0.03 (-1.33%)
Updated Aug 22, 2026, 4:31 PM
SID Score
6.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 94.81M
- P/E ratio
- -3.26
- Dividend yield
- 0.00%
- 52-week range
- $0.90 – $2.00
- Volume
- 753.35K
- Avg. volume
- 704.06K
Price performance
CRDL price history
1M range · 21 trading sessions · Daily adjusted prices
CRDL closed at $1.86 after 21 trading sessions, up 57.63% for the selected period.
- Last close
- $1.86
- Period change
- +57.63%
- Period low
- $1.15
- Period high
- $1.96
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $1.93 | $1.9319 | $1.855 | $1.86 | 753.35K |
| Aug 20, 2026 | $1.96 | $1.995 | $1.83 | $1.885 | 1.53M |
| Aug 19, 2026 | $1.92 | $1.965 | $1.86 | $1.96 | 1.75M |
| Aug 18, 2026 | $1.82 | $1.90 | $1.735 | $1.895 | 1.6M |
| Aug 17, 2026 | $1.73 | $1.94 | $1.73 | $1.80 | 2.33M |
| Aug 14, 2026 | $1.73 | $1.82 | $1.65 | $1.80 | 1.73M |
| Aug 13, 2026 | $1.49 | $1.77 | $1.49 | $1.71 | 2.14M |
| Aug 12, 2026 | $1.51 | $1.52 | $1.43 | $1.52 | 790.97K |
| Aug 11, 2026 | $1.49 | $1.53 | $1.445 | $1.50 | 776.24K |
| Aug 10, 2026 | $1.44 | $1.50 | $1.38 | $1.47 | 1.52M |
| Aug 7, 2026 | $1.36 | $1.425 | $1.35 | $1.42 | 327.19K |
| Aug 6, 2026 | $1.32 | $1.385 | $1.315 | $1.36 | 790.16K |
| Aug 5, 2026 | $1.36 | $1.38 | $1.31 | $1.34 | 1.07M |
| Aug 4, 2026 | $1.30 | $1.37 | $1.275 | $1.36 | 1.54M |
| Aug 3, 2026 | $1.29 | $1.33 | $1.21 | $1.31 | 778.74K |
| Jul 31, 2026 | $1.23 | $1.29 | $1.20 | $1.27 | 1.15M |
| Jul 30, 2026 | $1.16 | $1.24 | $1.14 | $1.21 | 897.98K |
| Jul 29, 2026 | $1.20 | $1.21 | $1.145 | $1.15 | 916.11K |
| Jul 28, 2026 | $1.16 | $1.225 | $1.1106 | $1.20 | 992.45K |
| Jul 27, 2026 | $1.20 | $1.21 | $1.15 | $1.155 | 552.38K |
| Jul 24, 2026 | $1.23 | $1.25 | $1.15 | $1.18 | 680.4K |
Latest CRDL news
The latest Smart Investors Daily articles mentioning CRDL.
Stock researchCompany · Overview
CRDL research
Overview
Company profile and research snapshot.
Company profile
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $8.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 12, 2026 | FIRST BERLIN EQUITY RESEARCH | Buy | — |
| May 11, 2026 | BROOKLINE CAPITAL MARKETS | Buy | — |
| Feb 25, 2026 | FIRST BERLIN EQUITY RESEARCH | Buy | — |
| Jan 21, 2026 | FIRST BERLIN EQUITY RESEARCH | Buy | — |
| Jan 20, 2026 | FIRST BERLIN EQUITY RESEARCH | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 5, 2026
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference in Boston, MA, on August 11, 2026, at 9:00 a.m. EDT.
Benzinga · Jul 14, 2026
HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 price target.
Benzinga · Jul 14, 2026
Cardiol Therapeutics Announces Publication Of Phase II MAvERIC Study Results In The Journal of the American Heart Association
The publication comes as the pivotal Phase III MAVERIC trial nears full patient enrollment. The publication describes clinical findings in which CardiolRx™ was associated with rapid and sustained reductions in
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
